Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Insmed reported revenue of $107.42 million for the quarter ended June 2025, reflecting an 18.9% increase year-over-year and a surprise of +3.87% over the Zacks Consensus Estimate of $103.42 million [1] - The company's EPS was -$1.70, an improvement from -$1.94 in the same quarter last year, but fell short of the consensus estimate of -$1.30, resulting in a surprise of -30.77% [1] Revenue Breakdown - U.S. revenue was $68.68 million, which was below the average estimate of $71.75 million from four analysts, representing a year-over-year increase of +7.7% [4] - Revenue from Europe and the rest of the world was $8.06 million, exceeding the average estimate of $6.57 million from three analysts, with a year-over-year increase of +48.3% [4] - Revenue from Japan reached $30.67 million, surpassing the average estimate of $26 million from three analysts, marking a year-over-year increase of +45.3% [4] Stock Performance - Insmed shares have returned +15.3% over the past month, outperforming the Zacks S&P 500 composite, which saw a +1.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]